The cholinergic system and depression

Behavioural Brain Research

Volumn 221, Issue 2, 2011, Pages 574-582

  Dagyte, Girstaute ^a   Den Boer, Johan A ^a   Trentani, Andrea ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Acetylcholine; Affective disorders; Antidepressants; Basolateral amygdala; Hippocampus; Prefrontal cortex; SCN

Indexed keywords

ACETYLCHOLINESTERASE; AGOMELATINE; ANTIDEPRESSANT AGENT; CHOLINE; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; DONEPEZIL; DYFLOS; EA 1701; GLUCOCORTICOID; GLUTAMIC ACID; INSECTICIDE; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR BLOCKING AGENT; PHYSOSTIGMINE; RESERPINE; UNCLASSIFIED DRUG;

ACETYLCHOLINE RELEASE; ATTENTION DEFICIT DISORDER; CHOLINERGIC SYSTEM; CHOLINERGIC TRANSMISSION; CHRONIC STRESS; COGNITIVE DEFECT; CONCENTRATION LOSS; DEPRESSION; DISEASE ASSOCIATION; DRUG ACTIVITY; ENZYME ACTIVITY; HIPPOCAMPUS; HUMAN; LONG TERM MEMORY; MEMORY CONSOLIDATION; MEMORY DISORDER; NEUROIMAGING; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SMOKING; STRESS;

ANIMALS; BRAIN; CHOLINERGIC ANTAGONISTS; CHOLINERGIC FIBERS; COGNITION DISORDERS; DEPRESSIVE DISORDER, MAJOR; HUMANS; MODELS, BIOLOGICAL; NEUROGENESIS; SYNAPTIC TRANSMISSION;

EID: 79955740698     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.02.023     Document Type: Review

References (171)

1. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia L.M. Neurobiology of depression. Neuron 2002, 34:13-25.
2. Wong M.L., Licinio J. Research and treatment approaches to depression. Nat Rev Neurosci 2001, 2:343-351.
3. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006, 7:137-151.
4. Maes M. Inflammatory and oxidative and nitrosative stress pathways underpinning chronic fatigue, somatization and psychosomatic symptoms. Curr Opin Psychiatry 2009, 22:75-83.
5. Krishnan V., Nestler E.J. The molecular neurobiology of depression. Nature 2008, 455:894-902.
6. Manji H.K., Drevets W.C., Charney D.S. The cellular neurobiology of depression. Nat Med 2001, 7:541-547.
7. Nutt D., Demyttenaere K., Janka Z., Aarre T., Bourin M., Canonico P.L., et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol 2007, 21:461-471.
8. Vaillant G.E. A comparison of antagonists of physostigmine-induced suppression of behavior. J Pharmacol Exp Ther 1967, 157:636-648.
9. Domino E.F., Olds M.E. Cholinergic inhibition of self-stimulation behavior. J Pharmacol Exp Ther 1968, 164:202-211.
10. Carlton P.L. Cholinergic mechanisms in the control of behavior by the brain. Psychol Rev 1963, 70:19-39.
11. Janowsky D.S., el-Yousef M.K., Davis J.M., Sekerke H.J. A cholinergic-adrenergic hypothesis of mania and depression. Lancet 1972, 2:632-635.
12. Rowntree D.W., Nevin S., Wilson A. The effects of diisopropylfluorophosphonate in schizophrenia and manic depressive psychosis. J Neurol Neurosurg Psychiatry 1950, 13:47-62.
13. Gershon S., Shaw F.H. Psychiatric sequelae of chronic exposure to organophosphorus insecticides. Lancet 1961, 1:1371-1374.
14. Bowers M.B., Goodman E., Sim V.M. Some behavioral changes in man following anticholinesterase administration. J Nerv Ment Dis 1964, 138:383-389.
15. Davis K.L., Hollister L.E., Overall J., Johnson A., Train K. Physostigmine: effects on cognition and affect in normal subjects. Psychopharmacology (Berl) 1976, 51:23-27.
16. Janowsky D.S., el-Yousef K., Davis J.M., Sekerke H.J. Parasympathetic suppression of manic symptoms by physostigmine. Arch Gen Psychiatry 1973, 28:542-547.
17. Janowsky D.S., el-Yousef M.K., Davis J.M. Acetylcholine and depression. Psychosom Med 1974, 36:248-257.
18. Tamminga C., Smith R.C., Chang S., Haraszti J.S., Davis J.M. Depression associated with oral choline. Lancet 1976, 2:905.
19. Davis K.L., Berger P.A., Hollister L.E., Barchas J.D. Cholinergic involvement in mental disorders. Life Sci 1978, 22:1865-1871.
20. Dilsaver S.C. Cholinergic mechanisms in depression. Brain Res 1986, 396:285-316.
21. Leong S.S., Brown W.A. Acetylcholine and affective disorder. J Neural Transm 1987, 70:295-312.
22. Goldman M.E., Erickson C.K. Effects of acute and chronic administration of antidepressant drugs on the central cholinergic nervous system. Comparison with anticholinergic drugs. Neuropharmacology 1983, 22:1215-1222.
23. Shytle R.D., Silver A.A., Lukas R.J., Newman M.B., Sheehan D.V., Sanberg P.R. Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry 2002, 7:525-535.
24. Howland R.H. The antidepressant effects of anticholinergic drugs. J Psychosoc Nurs Ment Health Serv 2009, 47:17-20.
25. Ferguson S.M., Brodkin J.D., Lloyd G.K., Menzaghi F. Antidepressant-like effects of the subtype-selective nicotinic acetylcholine receptor agonist, SIB-1508Y, in the learned helplessness rat model of depression. Psychopharmacology (Berl) 2000, 152:295-303.
26. Gatto G.J., Bohme G.A., Caldwell W.S., Letchworth S.R., Traina V.M., Obinu M.C., et al. TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects. CNS Drug Rev 2004, 10:147-166.
27. Steingard R.J., Yurgelun-Todd D.A., Hennen J., Moore J.C., Moore C.M., Vakili K., et al. Increased orbitofrontal cortex levels of choline in depressed adolescents as detected by in vivo proton magnetic resonance spectroscopy. Biol Psychiatry 2000, 48:1053-1061.
28. Charles H.C., Lazeyras F., Krishnan K.R., Boyko O.B., Payne M., Moore D. Brain choline in depression: in vivo detection of potential pharmacodynamic effects of antidepressant therapy using hydrogen localized spectroscopy. Prog Neuropsychopharmacol Biol Psychiatry 1994, 18:1121-1127.
29. Meyerson L.R., Wennogle L.P., Abel M.S., Coupet J., Lippa A.S., Rauh C.E., et al. Human brain receptor alterations in suicide victims. Pharmacol Biochem Behav 1982, 17:159-163.
30. Zavitsanou K., Katsifis A., Mattner F., Huang X.F. Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 2004, 29:619-625.
31. Stanley M. Cholinergic receptor binding in the frontal cortex of suicide victims. Am J Psychiatry 1984, 141:1432-1436.
32. Kaufmann C.A., Gillin J.C., Hill B., O'Laughlin T., Phillips I., Kleinman J.E., et al. Muscarinic binding in suicides. Psychiatry Res 1984, 12:47-55.
33. Gibbons A.S., Scarr E., McLean C., Sundram S., Dean B. Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects. J Affect Disord 2009, 116:184-191.
34. Fritze J., Lanczik M., Sofic E., Struck M., Riederer P. Cholinergic neurotransmission seems not to be involved in depression but possibly in personality. J Psychiatry Neurosci 1995, 20:39-48.
35. Austin M.P., Mitchell P., Goodwin G.M. Cognitive deficits in depression: possible implications for functional neuropathology. Br J Psychiatry 2001, 178:200-206.
36. Porter R.J., Gallagher P., Thompson J.M., Young A.H. Neurocognitive impairment in drug-free patients with major depressive disorder. Br J Psychiatry 2003, 182:214-220.
37. Clark L., Chamberlain S.R., Sahakian B.J. Neurocognitive mechanisms in depression: implications for treatment. Annu Rev Neurosci 2009, 32:57-74.
38. Deutsch J.A. The cholinergic synapse and the site of memory. Science 1971, 174:788-794.
39. Roland J.J., Mark K., Vetreno R.P., Savage L.M. Increasing hippocampal acetylcholine levels enhance behavioral performance in an animal model of diencephalic amnesia. Brain Res 2008, 1234:116-127.
40. van der Zee E.A., Streefland C., Strosberg A.D., Schroder H., Luiten P.G. Colocalization of muscarinic and nicotinic receptors in cholinoceptive neurons of the suprachiasmatic region in young and aged rats. Brain Res 1991, 542:348-352.
41. Schroder H., Giacobini E., Struble R.G., Luiten P.G., van der Zee E.A., Zilles K., et al. Muscarinic cholinoceptive neurons in the frontal cortex in Alzheimer's disease. Brain Res Bull 1991, 27:631-636.
42. Salin-Pascual R.J., de la Fuente J.R., Galicia-Polo L., Drucker-Colin R. Effects of transderman nicotine on mood and sleep in nonsmoking major depressed patients. Psychopharmacology (Berl) 1995, 121:476-479.
43. Laje R.P., Berman J.A., Glassman A.H. Depression and nicotine: preclinical and clinical evidence for common mechanisms. Curr Psychiatry Rep 2001, 3:470-474.
44. Lerman C., Caporaso N., Main D., Audrain J., Boyd N.R., Bowman E.D., et al. Depression and self-medication with nicotine: the modifying influence of the dopamine D4 receptor gene. Health Psychol 1998, 17:56-62.
45. Kendler K.S., Neale M.C., MacLean C.J., Heath A.C., Eaves L.J., Kessler R.C. Smoking and major depression. A causal analysis. Arch Gen Psychiatry 1993, 50:36-43.
46. George T.P., Vessicchio J.C., Termine A., Sahady D.M., Head C.A., Pepper W.T., et al. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology 2002, 26:75-85.
47. Sacco K.A., Termine A., Seyal A., Dudas M.M., Vessicchio J.C., Krishnan-Sarin S., et al. Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry 2005, 62:649-659.
48. Lippiello P.M., Beaver J.S., Gatto G.J., James J.W., Jordan K.G., Traina V.M., et al. TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity. CNS Neurosci Ther 2008, 14:266-277.
49. Levin E.D., Simon B.B. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berl) 1998, 138:217-230.
50. McKay B.E., Placzek A.N., Dani J.A. Regulation of synaptic transmission and plasticity by neuronal nicotinic acetylcholine receptors. Biochem Pharmacol 2007, 74:1120-1133.
51. Hasselmo M.E. The role of acetylcholine in learning and memory. Curr Opin Neurobiol 2006, 16:710-715.
52. Scarr E. Muscarinic receptors in psychiatric disorders-can we mimic 'health'?. Neurosignals 2009, 17:298-310.
53. Jerusalinsky D., Kornisiuk E., Izquierdo I. Cholinergic neurotransmission and synaptic plasticity concerning memory processing. Neurochem Res 1997, 22:507-515.
54. Power A.E., Vazdarjanova A., McGaugh J.L. Muscarinic cholinergic influences in memory consolidation. Neurobiol Learn Mem 2003, 80:178-193.
55. Comings D.E., Wu S., Rostamkhani M., McGue M., Iacono W.G., MacMurray J.P. Association of the muscarinic cholinergic 2 receptor (CHRM2) gene with major depression in women. Am J Med Genet 2002, 114:527-529.
56. Wang J.C., Hinrichs A.L., Stock H., Budde J., Allen R., Bertelsen S., et al. Evidence of common and specific genetic effects: association of the muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndrome. Hum Mol Genet 2004, 13:1903-1911.
57. Lucas-Meunier E., Fossier P., Baux G., Amar M. Cholinergic modulation of the cortical neuronal network. Pflugers Arch 2003, 446:17-29.
58. Egashira N., Matsumoto Y., Mishima K., Iwasaki K., Fujioka M., Matsushita M., et al. Low dose citalopram reverses memory impairment and electroconvulsive shock-induced immobilization. Pharmacol Biochem Behav 2006, 83:161-167.
59. Pollock B.G., Mulsant B.H., Rosen J., Sweet R.A., Mazumdar S., Bharucha A., et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002, 159:460-465.
60. Harmer C.J., Bhagwagar Z., Cowen P.J., Goodwin G.M. Acute administration of citalopram facilitates memory consolidation in healthy volunteers. Psychopharmacology (Berl) 2002, 163:106-110.
61. Marinho M.M., de Sousa F.C., de Bruin V.M., Vale M.R., Viana G.S. Effects of lithium, alone or associated with pilocarpine, on muscarinic and dopaminergic receptors and on phosphoinositide metabolism in rat hippocampus and striatum. Neurochem Int 1998, 33:299-306.
62. Gilad G.M. The stress-induced response of the septo-hippocampal cholinergic system. A vectorial outcome of psychoneuroendocrinological interactions. Psychoneuroendocrinology 1987, 12:167-184.
63. Finkelstein Y., Koffler B., Rabey J.M., Gilad G.M. Dynamics of cholinergic synaptic mechanisms in rat hippocampus after stress. Brain Res 1985, 343:314-319.
64. de Kloet E.R., Joels M., Holsboer F. Stress and the brain: from adaptation to disease. Nat Rev Neurosci 2005, 6:463-475.
65. McEwen B.S. Protection and damage from acute and chronic stress: allostasis and allostatic overload and relevance to the pathophysiology of psychiatric disorders. Ann N Y Acad Sci 2004, 1032:1-7.
66. Dagyte G., Van der Zee E.A., Postema F., Luiten P.G., Den Boer J.A., Trentani A., et al. Chronic but not acute foot-shock stress leads to temporary suppression of cell proliferation in rat hippocampus. Neuroscience 2009, 162:904-913.
67. Srikumar B.N., Raju T.R., Shankaranarayana Rao B.S. The involvement of cholinergic and noradrenergic systems in behavioral recovery following oxotremorine treatment to chronically stressed rats. Neuroscience 2006, 143:679-688.
68. Gold P.E. Acetylcholine modulation of neural systems involved in learning and memory. Neurobiol Learn Mem 2003, 80:194-210.
69. Newman M.B., Nazian S.J., Sanberg P.R., Diamond D.M., Shytle R.D. Corticosterone-attenuating and anxiolytic properties of mecamylamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry 2001, 25:609-620.
70. Mark G.P., Rada P.V., Shors T.J. Inescapable stress enhances extracellular acetylcholine in the rat hippocampus and prefrontal cortex but not the nucleus accumbens or amygdala. Neuroscience 1996, 74:767-774.
71. Dong Y., Mao J., Shangguan D., Zhao R., Liu G. Acetylcholine release in the hippocampus during the operant conditioned reflex and the footshock stimulus in rats. Neurosci Lett 2004, 369:121-125.
72. Mizoguchi K., Yuzurihara M., Ishige A., Sasaki H., Tabira T. Effect of chronic stress on cholinergic transmission in rat hippocampus. Brain Res 2001, 915:108-111.
73. Sunanda, Rao B.S., Raju T.R. Restraint stress-induced alterations in the levels of biogenic amines, amino acids, and AChE activity in the hippocampus. Neurochem Res 2000, 25:1547-1552.
74. Das A., Kapoor K., Sayeepriyadarshini A.T., Dikshit M., Palit G., Nath C. Immobilization stress-induced changes in brain acetylcholinesterase activity and cognitive function in mice. Pharmacol Res 2000, 42:213-217.
75. Tizabi Y., Gilad V.H., Gilad G.M. Effects of chronic stressors or corticosterone treatment on the septohippocampal cholinergic system of the rat. Neurosci Lett 1989, 105:177-182.
76. Douma B.R., Jansen K., Korte S.M., Buwalda B., Van der Zee E.A., Luiten P.G. Corticosterone modifies muscarinic receptor immunoreactivity in rat hippocampus. Neurosci Lett 1999, 268:41-44.
77. Ragozzino M.E., Wenk G.L., Gold P.E. Glucose attenuates a morphine-induced decrease in hippocampal acetylcholine output: an in vivo microdialysis study in rats. Brain Res 1994, 655:77-82.
78. Ragozzino M.E., Unick K.E., Gold P.E. Hippocampal acetylcholine release during memory testing in rats: augmentation by glucose. Proc Natl Acad Sci USA 1996, 93:4693-4698.
79. McEwen B.S. The neurobiology of stress: from serendipity to clinical relevance. Brain Res 2000, 886:172-189.
80. McEwen B.S. Effects of adverse experiences for brain structure and function. Biol Psychiatry 2000, 48:721-731.
81. Luine V., Villegas M., Martinez C., McEwen B.S. Repeated stress causes reversible impairments of spatial memory performance. Brain Res 1994, 639:167-170.
82. Conrad C.D., Galea L.A., Kuroda Y., McEwen B.S. Chronic stress impairs rat spatial memory on the Y maze, and this effect is blocked by tianeptine pretreatment. Behav Neurosci 1996, 110:1321-1334.
83. Gaykema R.P., Luiten P.G., Nyakas C., Traber J. Cortical projection patterns of the medial septum-diagonal band complex. J Comp Neurol 1990, 293:103-124.
84. Woolf N.J. Cholinergic systems in mammalian brain and spinal cord. Prog Neurobiol 1991, 37:475-524.
85. Sapolsky R.M. Potential behavioral modification of glucocorticoid damage to the hippocampus. Behav Brain Res 1993, 57:175-182.
86. Woolley C.S., Gould E., McEwen B.S. Exposure to excess glucocorticoids alters dendritic morphology of adult hippocampal pyramidal neurons. Brain Res 1990, 531:225-231.
87. Moghaddam B. Stress preferentially increases extraneuronal levels of excitatory amino acids in the prefrontal cortex: comparison to hippocampus and basal ganglia. J Neurochem 1993, 60:1650-1657.
88. Moghaddam B., Bolinao M.L., Stein-Behrens B., Sapolsky R. Glucocorticoids mediate the stress-induced extracellular accumulation of glutamate. Brain Res 1994, 655:251-254.
89. Watanabe Y., Gould E., Cameron H.A., Daniels D.C., McEwen B.S. Phenytoin prevents stress- and corticosterone-induced atrophy of CA3 pyramidal neurons. Hippocampus 1992, 2:431-435.
90. Lee A.L., Ogle W.O., Sapolsky R.M. Stress and depression: possible links to neuron death in the hippocampus. Bipolar Disord 2002, 4:117-128.
91. Riederer P., Hoyer S. From benefit to damage. Glutamate and advanced glycation end products in Alzheimer brain. J Neural Transm 2006, 113:1671-1677.
92. Campbell S., MacQueen G. An update on regional brain volume differences associated with mood disorders. Curr Opin Psychiatry 2006, 19:25-33.
93. Sheline Y.I. Neuroimaging studies of mood disorder effects on the brain. Biol Psychiatry 2003, 54:338-352.
94. Stockmeier C.A., Mahajan G.J., Konick L.C., Overholser J.C., Jurjus G.J., Meltzer H.Y., et al. Cellular changes in the postmortem hippocampus in major depression. Biol Psychiatry 2004, 56:640-650.
95. van der Zee E.A., Luiten P.G. Muscarinic acetylcholine receptors in the hippocampus, neocortex and amygdala: a review of immunocytochemical localization in relation to learning and memory. Prog Neurobiol 1999, 58:409-471.
96. Semba K., Fibiger H.C. Afferent connections of the laterodorsal and the pedunculopontine tegmental nuclei in the rat: a retro- and antero-grade transport and immunohistochemical study. J Comp Neurol 1992, 323:387-410.
97. Houser C.R., Crawford G.D., Barber R.P., Salvaterra P.M., Vaughn J.E. Organization and morphological characteristics of cholinergic neurons: an immunocytochemical study with a monoclonal antibody to choline acetyltransferase. Brain Res 1983, 266:97-119.
98. Craig L.A., Hong N.S., Kopp J., McDonald R.J. Emergence of spatial impairment in rats following specific cholinergic depletion of the medial septum combined with chronic stress. Eur J Neurosci 2008, 27:2262-2271.
99. Cooper-Kuhn C.M., Winkler J., Kuhn H.G. Decreased neurogenesis after cholinergic forebrain lesion in the adult rat. J Neurosci Res 2004, 77:155-165.
100. Van der Borght K., Mulder J., Keijser J.N., Eggen B.J., Luiten P.G., Van der Zee E.A. Input from the medial septum regulates adult hippocampal neurogenesis. Brain Res Bull 2005, 67:117-125.
101. Mohapel P., Leanza G., Kokaia M., Lindvall O. Forebrain acetylcholine regulates adult hippocampal neurogenesis and learning. Neurobiol Aging 2005, 26:939-946.
102. Cohen J.E., Zimmerman G., Melamed-Book N., Friedman A., Dori A., Soreq H. Transgenic inactivation of acetylcholinesterase impairs homeostasis in mouse hippocampal granule cells. Hippocampus 2008, 18:182-192.
103. Kotani S., Yamauchi T., Teramoto T., Ogura H. Pharmacological evidence of cholinergic involvement in adult hippocampal neurogenesis in rats. Neuroscience 2006, 142:505-514.
104. Kaneko N., Okano H., Sawamoto K. Role of the cholinergic system in regulating survival of newborn neurons in the adult mouse dentate gyrus and olfactory bulb. Genes Cells 2006, 11:1145-1159.
105. Jacobs B.L., Praag H., Gage F.H. Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol Psychiatry 2000, 5:262-269.
106. Duman R.S. Depression: a case of neuronal life and death?. Biol Psychiatry 2004, 56:140-145.
107. Gould E., Tanapat P. Stress and hippocampal neurogenesis. Biol Psychiatry 1999, 46:1472-1479.
108. Mirescu C., Gould E. Stress and adult neurogenesis. Hippocampus 2006, 16:233-238.
109. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
110. Sapolsky R.M. Is impaired neurogenesis relevant to the affective symptoms of depression?. Biol Psychiatry 2004, 56:137-139.
111. Eisch A.J., Cameron H.A., Encinas J.M., Meltzer L.A., Ming G.L., Overstreet-Wadiche L.S. Adult neurogenesis, mental health, and mental illness: hope or hype?. J Neurosci 2008, 28:11785-11791.
112. Bessa J.M., Ferreira D., Melo I., Marques F., Cerqueira J.J., Palha J.A., et al. The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling. Mol Psychiatry 2009, 14:764-773. 739.
113. Scoville W.B., Milner B. Loss of recent memory after bilateral hippocampal lesions. 1957. J Neuropsychiatry Clin Neurosci 2000, 12:103-113.
114. Burgess N., Maguire E.A., O'Keefe J. The human hippocampus and spatial and episodic memory. Neuron 2002, 35:625-641.
115. Squire L.R., Stark C.E., Clark R.E. The medial temporal lobe. Annu Rev Neurosci 2004, 27:279-306.
116. Sheline Y.I., Sanghavi M., Mintun M.A., Gado M.H. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci 1999, 19:5034-5043.
117. Becker S., Wojtowicz J.M. A model of hippocampal neurogenesis in memory and mood disorders. Trends Cognit Sci 2007, 11:70-76.
118. Sheline Y.I., Wang P.W., Gado M.H., Csernansky J.G., Vannier M.W. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 1996, 93:3908-3913.
119. Brown E.S., Woolston D.J., Frol A., Bobadilla L., Khan D.A., Hanczyc M., et al. Hippocampal volume, spectroscopy, cognition, and mood in patients receiving corticosteroid therapy. Biol Psychiatry 2004, 55:538-545.
120. Duman R.S., Malberg J., Thome J. Neural plasticity to stress and antidepressant treatment. Biol Psychiatry 1999, 46:1181-1191.
121. Sapolsky R.M. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000, 57:925-935.
122. Gould E., Tanapat P., Hastings N.B., Shors T.J. Neurogenesis in adulthood: a possible role in learning. Trends Cognit Sci 1999, 3:186-192.
123. Sapolsky R.M. Stress and plasticity in the limbic system. Neurochem Res 2003, 28:1735-1742.
124. Leuner B., Gould E., Shors T.J. Is there a link between adult neurogenesis and learning?. Hippocampus 2006, 16:216-224.
125. Shors T.J., Townsend D.A., Zhao M., Kozorovitskiy Y., Gould E. Neurogenesis may relate to some but not all types of hippocampal-dependent learning. Hippocampus 2002, 12:578-584.
126. Van der Borght K., Meerlo P., Luiten P.G., Eggen B.J., Van der Zee E.A. Effects of active shock avoidance learning on hippocampal neurogenesis and plasma levels of corticosterone. Behav Brain Res 2005, 157:23-30.
127. Feng R., Rampon C., Tang Y.P., Shrom D., Jin J., Kyin M., et al. Deficient neurogenesis in forebrain-specific presenilin-1 knockout mice is associated with reduced clearance of hippocampal memory traces. Neuron 2001, 32:911-926.
128. Van der Borght K., Wallinga A.E., Luiten P.G., Eggen B.J., Van der Zee E.A. Morris water maze learning in two rat strains increases the expression of the polysialylated form of the neural cell adhesion molecule in the dentate gyrus but has no effect on hippocampal neurogenesis. Behav Neurosci 2005, 119:926-932.
129. Carlen M., Cassidy R.M., Brismar H., Smith G.A., Enquist L.W., Frisen J. Functional integration of adult-born neurons. Curr Biol 2002, 12:606-608.
130. Akirav I., Kozenicky M., Tal D., Sandi C., Venero C., Richter-Levin G. A facilitative role for corticosterone in the acquisition of a spatial task under moderate stress. Learn Mem 2004, 11:188-195.
131. Kitamura T., Saitoh Y., Takashima N., Murayama A., Niibori Y., Ageta H., et al. Adult neurogenesis modulates the hippocampus-dependent period of associative fear memory. Cell 2009, 139:814-827.
132. Van der Borght K., Havekes R., Bos T., Eggen B.J., Van der Zee E.A. Exercise improves memory acquisition and retrieval in the Y-maze task: relationship with hippocampal neurogenesis. Behav Neurosci 2007, 121:324-334.
133. Rogers M.A., Kasai K., Koji M., Fukuda R., Iwanami A., Nakagome K., et al. Executive and prefrontal dysfunction in unipolar depression: a review of neuropsychological and imaging evidence. Neurosci Res 2004, 50:1-11.
134. Koenigs M., Grafman J. The functional neuroanatomy of depression: distinct roles for ventromedial and dorsolateral prefrontal cortex. Behav Brain Res 2009, 201:239-243.
135. Seeger T., Fedorova I., Zheng F., Miyakawa T., Koustova E., Gomeza J., et al. M2 muscarinic acetylcholine receptor knock-out mice show deficits in behavioral flexibility, working memory, and hippocampal plasticity. J Neurosci 2004, 24:10117-10127.
136. Fales C.L., Barch D.M., Rundle M.M., Mintun M.A., Snyder A.Z., Cohen J.D., et al. Altered emotional interference processing in affective and cognitive-control brain circuitry in major depression. Biol Psychiatry 2008, 63:377-384.
137. Sheline Y.I., Barch D.M., Donnelly J.M., Ollinger J.M., Snyder A.Z., Mintun M.A. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biol Psychiatry 2001, 50:651-658.
138. McDonald R.J., Devan B.D., Hong N.S. Multiple memory systems: the power of interactions. Neurobiol Learn Mem 2004, 82:333-346.
139. LeDoux J. The emotional brain, fear, and the amygdala. Cell Mol Neurobiol 2003, 23:727-738.
140. Davis M., Rainnie D., Cassell M. Neurotransmission in the rat amygdala related to fear and anxiety. Trends Neurosci 1994, 17:208-214.
141. McGaugh J.L. The amygdala modulates the consolidation of memories of emotionally arousing experiences. Annu Rev Neurosci 2004, 27:1-28.
142. Woolf N.J., Butcher L.L. Cholinergic projections to the basolateral amygdala: a combined Evans Blue and acetylcholinesterase analysis. Brain Res Bull 1982, 8:751-763.
143. van der Zee E.A., Roozendaal B., Bohus B., Koolhaas J.M., Luiten P.G. Muscarinic acetylcholine receptor immunoreactivity in the amygdala-I. Cellular distribution correlated with fear-induced behavior. Neuroscience 1997, 76:63-73.
144. Roozendaal B., van der Zee E.A., Hensbroek R.A., Maat H., Luiten P.G., Koolhaas J.M., et al. Muscarinic acetylcholine receptor immunoreactivity in the amygdala-II. Fear-induced plasticity. Neuroscience 1997, 76:75-83.
145. Power A.E., McGaugh J.L. Phthalic acid amygdalopetal lesion of the nucleus basalis magnocellularis induces reversible memory deficits in rats. Neurobiol Learn Mem 2002, 77:372-388.
146. Schroeder J.P., Packard M.G. Posttraining intra-basolateral amygdala scopolamine impairs food- and amphetamine-induced conditioned place preferences. Behav Neurosci 2002, 116:922-927.
147. Vazdarjanova A., McGaugh J.L. Basolateral amygdala is involved in modulating consolidation of memory for classical fear conditioning. J Neurosci 1999, 19:6615-6622.
148. McGaugh J.L., McIntyre C.K., Power A.E. Amygdala modulation of memory consolidation: interaction with other brain systems. Neurobiol Learn Mem 2002, 78:539-552.
149. McGaugh J.L. Memory-a century of consolidation. Science 2000, 287:248-251.
150. McGaugh J.L., Roozendaal B. Role of adrenal stress hormones in forming lasting memories in the brain. Curr Opin Neurobiol 2002, 12:205-210.
151. Roozendaal B. 1999 Curt P. Richter award. Glucocorticoids and the regulation of memory consolidation. Psychoneuroendocrinology 2000, 25:213-238.
152. Rainnie D.G., Bergeron R., Sajdyk T.J., Patil M., Gehlert D.R., Shekhar A. Corticotrophin releasing factor-induced synaptic plasticity in the amygdala translates stress into emotional disorders. J Neurosci 2004, 24:3471-3479.
153. de Quervain D.J., Aerni A., Schelling G., Roozendaal B. Glucocorticoids and the regulation of memory in health and disease. Front Neuroendocrinol 2009, 30:358-370.
154. Roozendaal B., McReynolds J.R., McGaugh J.L. The basolateral amygdala interacts with the medial prefrontal cortex in regulating glucocorticoid effects on working memory impairment. J Neurosci 2004, 24:1385-1392.
155. Bina K.G., Rusak B., Semba K. Localization of cholinergic neurons in the forebrain and brainstem that project to the suprachiasmatic nucleus of the hypothalamus in rat. J Comp Neurol 1993, 335:295-307.
156. Castillo-Ruiz A., Nunez A.A. Cholinergic projections to the suprachiasmatic nucleus and lower subparaventricular zone of diurnal and nocturnal rodents. Brain Res 2007, 1151:91-101.
157. Tuma J., Strubbe J.H., Mocaer E., Koolhaas J.M. Anxiolytic-like action of the antidepressant agomelatine (S 20098) after a social defeat requires the integrity of the SCN. Eur Neuropsychopharmacol 2005, 15:545-555.
158. Turek F.W. From circadian rhythms to clock genes in depression. Int Clin Psychopharmacol 2007, 22(Suppl. 2):S1-S8.
159. Lam R.W. Addressing circadian rhythm disturbances in depressed patients. J Psychopharmacol 2008, 22:13-18.
160. Klaffke S., Staedt J. Sundowning and circadian rhythm disorders in dementia. Acta Neurol Belg 2006, 106:168-175.
161. Van der Zee E.A., Biemans B.A., Gerkema M.P., Daan S. Habituation to a test apparatus during associative learning is sufficient to enhance muscarinic acetylcholine receptor-immunoreactivity in rat suprachiasmatic nucleus. J Neurosci Res 2004, 78:508-519.
162. Starkstein S.E., Mizrahi R., Power B.D. Depression in Alzheimer's disease: phenomenology, clinical correlates and treatment. Int Rev Psychiatry 2008, 20:382-388.
163. Popoli M. Agomelatine: innovative pharmacological approach in depression. CNS Drugs 2009, 23(Suppl. 2):27-34.
164. Millan M.J., Gobert A., Lejeune F., Dekeyne A., Newman-Tancredi A., Pasteau V., et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003, 306:954-964.
165. Audinot V., Mailliet F., Lahaye-Brasseur C., Bonnaud A., Le Gall A., Amosse C., et al. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol 2003, 367:553-561.
166. Conboy L., Tanrikut C., Zoladz P.R., Campbell A.M., Park C.R., Gabriel C., et al. The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (NCAM) expression in the hippocampus of rats. Int J Neuropsychopharmacol 2009, 12:329-341.
167. Banasr M., Soumier A., Hery M., Mocaer E., Daszuta A. Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biol Psychiatry 2006, 59:1087-1096.
168. Soumier A., Banasr M., Lortet S., Masmejean F., Bernard N., Kerkerian-Le-Goff L., et al. Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacology 2009, 34:2390-2403.
169. Dagyte G, Trentani A, Postema F, Luiten PG, Den Boer JA, Gabriel C, Mocaer E, Meerlo P, Van der Zee EA. The novel antidepressant agomelatine normalizes hippocampal neuronal activity and promotes neurogenesis in chronically stressed rats. CNS Neurosci Ther; in press.
170. Picciotto M.R., Addy N.A., Mineur Y.S., Brunzell D.H. It is not " either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog Neurobiol 2008, 84:329-342.
171. Bruel-Jungerman E, Lucassen PJ, Francis F. Cholinergic influences on cortical development and adult neurogenesis. Behav Brain Res 2010; this issue.